Peptide YY Fragment 3-36 human
Peptide YY Fragment 3-36 human structure
|
Common Name | Peptide YY Fragment 3-36 human | ||
|---|---|---|---|---|
| CAS Number | 126339-09-1 | Molecular Weight | 3980.42 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C176H272N52O54 | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
Use of Peptide YY Fragment 3-36 humanPeptide YY (PYY) (3-36), human is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite. |
| Name | Peptide YY (PYY) (3-36), human |
|---|---|
| Synonym | More Synonyms |
| Description | Peptide YY (PYY) (3-36), human is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite. |
|---|---|
| Related Catalog | |
| Target |
Y2 receptor[1] |
| In Vitro | Peptide YY (PYY) (3-36), human is a Y2 receptor agonist, generated via cleaving the first two amino acids at the N terminus of PYY1-36 by enzyme dipeptidyl peptidase-IV (DPP-IV), and can reduces food intake[1]. |
| In Vivo | In mice, actinonin significantly prolongs the anorectic effect of PYY3-36 (50 nmol/kg) and maintains higher PYY3-36 plasma levels than treatment with PYY3-36 alone[1]. |
| Animal Admin | Mice[1] Mice are divided into four treatment groups and administered an injection (maximum volume, 100 μL, sc) of either: 1) saline (n = 10), 2) phosphoramidon (10 mg/kg) (n = 10), 3) PYY3-36 (50 nmol/kg) (n = 10), or 4) PYY3-36 (50 nmol/kg) and phosphoramidon (10 mg/kg) (n = 10). This dose of phosphoramidon inhibits NEP activity for 4 h. Body weight is measured at 0 and 24 h after injection. Food intake is measured at 1, 2, 3, 4, 8, and 24 h after injection[1]. |
| References |
| Molecular Formula | C176H272N52O54 |
|---|---|
| Molecular Weight | 3980.42 |
| Appearance of Characters | lyophilized powder |
| Storage condition | −20°C |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
|
Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226.
Br. J. Pharmacol. 116 , 2245-2250, (1995) 1. We have characterized pharmacologically the receptor subtype(s) responsible for the neuropeptide Y (NPY)-induced vasoconstriction in human cerebral arteries. NPY, PYY and several of their derivativ... |
|
|
Peptide YY and neuropeptide Y: two peptides intimately involved in electrolyte homeostasis.
Trends Pharmacol. Sci. 17 , 436-438, (1996)
|
|
|
Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats.
Br. J. Pharmacol. 118 , 237-242, (1996) 1. The Y receptor subtype involved in the antagonism by neuropeptide Y (NPY) of intracisternal corticotropin-releasing factor (CRF)-induced inhibition of gastric acid secretion was studied in urethane... |
| MFCD00165623 |